LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

LLY

1,096.53

-1.32%↓

JNJ

228.19

-2.26%↓

ABBV

216.7

-2.01%↓

UNH

400.27

+0.24%↑

NVS

146.82

-2.48%↓

Search

Bio-Techne Corp

Fermé

SecteurSoins de santé

57.69 4.97

Résumé

Variation du prix de l'action

24h

Actuel

Min

56.94

Max

58.08

Chiffres clés

By Trading Economics

Revenu

13M

51M

Ventes

16M

311M

P/E

Moyenne du Secteur

80.243

49.712

BPA

0.53

Rendement du dividende

0.59

Marge bénéficiaire

16.392

Employés

3,100

EBITDA

21M

99M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+3.37% upside

Dividendes

By Acuity

Rendement du dividende

Moyenne du Secteur

0.59%

2.36%

Prochains Résultats

5 août 2026

Date du Prochain Dividende

28 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

230M

8.8B

Ouverture précédente

52.72

Clôture précédente

57.69

Sentiment de l'Actualité

By Acuity

76%

24%

301 / 342 Classement par Healthcare

Bio-Techne Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

À Propos Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat